• Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B 

      Olsen, Oddrun Elise; Wader, Karin Fahl; Hella, Hanne; Mylin, Anne K.; Turesson, Ingemar; Nesthus, Ingerid; Waage, Anders; Sundan, Anders; Holien, Toril (Journal article; Peer reviewed, 2015)
      Background: Activins are members of the TGF-β family of ligands that have multiple biological functions in embryonic stem cells as well as in differentiated tissue. Serum levels of activin A were found to be elevated ...
    • Artesunate shows potent anti-tumor activity in B-cell lymphoma 

      Våtsveen, Thea Kristin; Myhre, Marit Renee; Steen, Chloe Beate; Wälchli, Sébastien; Lingjærde, Ole Christian; Bai, Baoyan; Dillard, Pierre; Theodossiou, Theodossis; Holien, Toril; Sundan, Anders; Inderberg, Else Marit; Smeland, Erlend B; Myklebust, June; Oksvold, Morten Pedersen (Journal article; Peer reviewed, 2018)
      Background Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified ...
    • Biomarker discovery in multiple myeloma progression by quantitative proteomics 

      Dikic, Aida (Doctoral theses at NTNU;2018:305, Doctoral thesis, 2018)
      SAMMENDRAG Myelomatose (multipel myelom, benmargskreft) er en krefttype som skyldes ukontrollert vekst av plasmaceller i benmarg. Det er den nest vanligste hematologiske kreftformen og rammer ca. 300 personer i Norge hvert ...
    • Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin 

      Olsen, Oddrun Elise; Wader, Karin Fahl; Misund, Kristine; Våtsveen, Thea Kristin; Rø, Torstein Baade; Mylin, Anne K.; Turesson, I; Størdal, Berit Fladvad; Moen, Siv Helen; Standal, Therese; Waage, Anders; Sundan, Anders; Holien, Toril (Journal article; Peer reviewed, 2014)
      Multiple myeloma is a malignancy of plasma cells predominantly located in the bone marrow. A number of bone morphogenetic proteins (BMPs) induce apoptosis in myeloma cells in vitro, and with this study we add BMP-9 to the ...
    • BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis 

      Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar; Myklebost, Ola; Hovig, Eivind; Nakken, Sigve; Vodak, Daniel; Meza-Zepeda, Leonardo A.; Sandvik, Arne Kristian; Wader, Karin Fahl; Misund, Kristine; Sundan, Anders; Aarset, Harald; Waage, Anders (Journal article; Peer reviewed, 2015)
      In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF ...
    • Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells 

      Moen, Siv Helen; Westhrin, Marita; Zahoor, Muhammad; Nikolai N., Nørgaard; Hella, Hanne; Størdal, Berit Fladvad; Sundan, Anders; Nilsen, Nadra J.; Sponaas, Anne-Marit; Standal, Therese (Journal article; Peer reviewed, 2016)
      Introduction: Mesenchymal stem cells, also called mesenchymal stromal cells, MSCs, have great potential in stem cell therapy partly due to their immunosuppressive properties. How these cells respond to chronic inflammatory ...
    • Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model 

      Follin-Arbelet, Virginie; Hofgaard, Peter Olaf; Hauglin, Harald; Naderi, Soheil; Sundan, Anders; Blomhoff, Rune; Bogen, Bjarne; Blomhoff, Heidi Kiil (Journal article; Peer reviewed, 2011)
      Background Multiple myeloma is an incurable disease requiring the development of effective therapies which can be used clinically. We have elucidated the potential for manipulating the cAMP signaling pathway as a target ...
    • Cytotoxicity of poly(Alkyl cyanoacrylate) nanoparticles 

      Sulheim, Einar; Iversen, Tore Geir; To, Vu; Klinkenberg, Geir; Sletta, Håvard; Schmid, Ruth; Hatletveit, Anne Rein; Wågbø, Ane Marit; Sundan, Anders; Skotland, Tore; Sandvig, Kirsten; Mørch, Ýrr Asbjørg (Journal article; Peer reviewed, 2017)
      Although nanotoxicology has become a large research field, assessment of cytotoxicity is often reduced to analysis of one cell line only. Cytotoxicity of nanoparticles is complex and should, preferentially, be evaluated ...
    • Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids 

      Wang, Huabo; Teriete, Peter; Hu, Angela; Raveendra-Panickar, Dhanya; Pendelton, Kelsey; Lazo, John S; Eiseman, Julie; Holien, Toril; Misund, Kristine; Oliynyk, Ganna; Arsenian-Henriksson, Marie; Cosford, Nicholas DP; Sundan, Anders; Prochownik, Edward V (Journal article; Peer reviewed, 2015)
      Many oncogenic signals originate from abnormal protein-protein interactions that are potential targets for small molecule inhibitors. However, the therapeutic disruption of these interactions has proved elusive. We report ...
    • Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro 

      Våtsveen, Thea Kristin; Sponaas, Anne Marit; Tian, Erming; Zhang, Qing; Misund, Kristine; Sundan, Anders; Børset, Magne; Waage, Anders; Brede, Gaute (Journal article; Peer reviewed, 2016)
      Background: Multiple myeloma is an incurable complex disease characterized by clonal proliferation of malignant plasma cells in a hypoxic bone marrow environment. Hypoxia-dependent erythropoietin (EPO)-receptor (EPOR) ...
    • Establishment of Multiple Myeloma Cell lines with Hepatocyte growth factor (HGF) overexpression and knockdown 

      Qadir, Fouzia (Master thesis, 2013)
      Multiple myeloma is the malignancy of plasma cells which causes 0.9 % of all cancer related deaths. These malignant plasma cells acquire chromosomal abnormalities and complex genetic instability. Hepatocyte growth factor ...
    • Genetic biomarkers in multiple myeloma 

      Rustad, Even Holth (Doctoral theses at NTNU;2019: 223, Doctoral thesis, 2019)
      Multiple myeloma is a cancer of plasma cells in the bone marrow that accounts for 2 % of cancer cases globally. Improved understanding of the molecular basis of this disease has resulted in new treatment options and prolonged ...
    • Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss 

      Zahoor, Muhammad; Westhrin, Marita; Aass, Kristin Roseth; Moen, Siv Helen; Misund, Kristine; Psonka-Antonczyk, Katarzyna Maria; Giliberto, Mariaserena; Buene, Glenn; Sundan, Anders; Waage, Anders; Sponaas, Anne-Marit; Standal, Therese (Journal article; Peer reviewed, 2017)
      Multiple myeloma (MM) is a hematologic cancer characterized by expansion of malignant plasma cells in the bone marrow. Most patients develop an osteolytic bone disease, largely caused by increased osteoclastogenesis. The ...
    • Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients 

      Rampa, Christoph Samuel; Tian, Erming; Våtsveen, Thea Kristin; Buene, Glenn; Slørdahl, Tobias Schmidt; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2014)
      Background Hepatocyte growth factor (HGF) is a pleiotropic cytokine which can lead to cancer cell proliferation, migration and metastasis. In multiple myeloma (MM) patients it is an abundant component of the bone marrow. ...
    • Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells 

      Starheim, Kristian Kobbenes; Holien, Toril; Misund, Kristine; Johansson, Ida; Baranowska, Katarzyna Anna; Sponaas, Anne Marit; Hella, Hanne; Buene, Glenn; Waage, Anders; Sundan, Anders; Bjørkøy, Geir (Journal article; Peer reviewed, 2016)
      Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies. The proteasome inhibitor bortezomib has improved treatment significantly, ...
    • Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells. 

      Zub, Kamila Anna; Sousa, Mirta; Sarno, Antonio; Sharma, Animesh; Demirovic, Aida; Rao, Shalini; Young, Clifford; Aas, Per Arne; Ericsson, Ida; Sundan, Anders; Jensen, Ole Nørregaard; Slupphaug, Geir (Journal article; Peer reviewed, 2015)
      Alkylating agents are widely used chemotherapeutics in the treatment of many cancers, including leukemia, lymphoma, multiple myeloma, sarcoma, lung, breast and ovarian cancer. Melphalan is the most commonly used chemotherapeutic ...
    • Monitoring multiple myeloma by quantification of recurrent mutations in serum 

      Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril; Standal, Therese; Børset, Magne; Beisvag, Vidar; Myklebost, Ola; Meza, Leonardo Zepeda; Hong, Yan Dai; Sundan, Anders; Waage, Anders (Journal article; Peer reviewed, 2017)
      Circulating tumor DNA is a promising biomarker to monitor tumor load and genome alterations. We explored the presence of circulating tumor DNA in multiple myeloma patients and its relation to disease activity during long-term ...
    • Multiple Myeloma-study of cellular sensitivity to proteasome inhibitors 

      Baranowska, Katarzyna Anna (Doctoral theses at NTNU;2018:273, Doctoral thesis, 2018)
      Myelomatose (benmargskreft) – en studie av kreftcellenes følsomhet for kreftmedisiner i gruppen proteasomhemmere Myelomatose er en kreftform som utvikler seg i beinmargen og karakteriseres av ukontrollert vekst av de ...
    • MYC amplifications in myeloma cell lines; correlation with MYC-inhibitor efficacy 

      Holien, Toril; Misund, Kristine; Olsen, Oddrun Elise; Baranowska, Katarzyna Anna; Buene, Glenn; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2015)
      In multiple myeloma, elevated MYC expression is related to disease initiation and progression. We found that in myeloma cell lines, MYC gene amplifications were common and correlated with MYC mRNA and protein. In primary ...
    • Myeloma-derived extracellular vesicles mediate HGF/c-Met signaling in osteoblast-like cells 

      Strømme, Olaf; Psonka Antonczyk, Katarzyna Maria; Stokke, Bjørn Torger; Sundan, Anders; Arum, Carl-Jørgen; Brede, Gaute (Journal article; Peer reviewed, 2019)
      Multiple myeloma is an incurable cancer of antibody-producing plasma cells. Hepatocyte growth factor (HGF), a cytokine aberrantly expressed in half of myeloma patients, is involved in myeloma pathogenesis by enhancing ...